Clinical trial Recruiting at 1 site Interventional Ages 14 to 17

Investigating brain processes related to rewards in adolescents

Official title: Neuromelanin MRI: A Tool for Non-invasive Investigation of Dopaminergic Abnormalities in Adolescent Substance Use

Run by Stony Brook University · NCT06369623 · Data updated 2026-11-12

This study is looking at how the brain's reward system works in teenagers to see if it can help us understand and prevent substance use problems.

Quick facts

Study typeInterventional
Ages14 Years to 17 Years
SexAll
Enrollment300 (estimated)
SponsorStony Brook University
Academic / other
Locations1 site (Stony Brook, New York)
StatusRecruiting
StartedApril 6, 2024
Main results expectedNovember 30, 2028
Study endsNovember 30, 2028
Registry record updatedMay 15, 2025
Trial IDNCT06369623 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are English-speaking males and females aged 14-17 who can provide assent and have parental consent.

Probably not a fit

Patients with recent substance use, severe medical conditions, or those on medications affecting cerebral function may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study will enroll 300 adolescents aged 14-17 to explore the relationship between substance use and dopamine function through neuromelanin-sensitive MRI and functional brain imaging. Participants will undergo three in-person assessments over 36 months, including a baseline evaluation, an 18-month follow-up, and a 36-month follow-up, alongside remote assessments of substance use every 90 days. The study aims to identify brain mechanisms that could inform future treatments for preventing substance use disorders in youth.

Why it matters

Potential benefit: If successful, this research could lead to targeted interventions that prevent the onset of substance use disorders in adolescents.

How similar studies have gone: While this approach is novel in its specific focus on adolescent substance use and dopamine function, similar studies have shown promise in understanding reward-related neural processes.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Males and females ages 14-17 years-old;
* English-speaking for assent and interview completion;
* Capacity to provide assent.
* For parents, the inclusion criteria will be willing and capacity to provide parental permission/consent.

Exclusion Criteria:

* current (within 6 months) use of medication that may affect cerebral function
* history of severe medical or neurological illness, including stroke or seizure;
* history of head trauma with loss of consciousness;
* presence of metal in the body;
* pregnancy or breastfeeding;
* recent drug or alcohol use determined by positive urine toxicology or breathalyzer (to validate self-report assessment of substance use history);
* lifetime use of psychotropic or other medication that could likely influence dopamine function, namely stimulant medication or antipsychotic medication, except a subgroup of 25 youth with history of prescribed stimulant medication and a subgroup of 15 youth with history antipsychotic medication will be enrolled for comparison purposes.

Where it's running

  • Stony Brook Medicine
    Stony Brook, New York, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.